CWP
VRTX icon

Capital Wealth Planning’s Vertex Pharmaceuticals VRTX Stock Holding History

Capital Wealth Planning’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-517
Closed -$251K – 158
2025
Q1 		$251K Buy
+517
New +$241K ﹤0.01% 131
2023
Q1 		– Sell
-710
Closed -$205K – 162
2022
Q4 		$205K Buy
+710
New +$216K ﹤0.01% 96

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital Wealth Planning's VRTX Position: Q2 2025 in Review

Capital Wealth Planning sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 517 shares — an estimated $251K sold.

Capital Wealth Planning first reported a position in VRTX in Q4 2022 and held it in 2 quarters. The position peaked at $251K in Q1 2025. 1,562 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

  • Capital Wealth Planning reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Capital Wealth Planning sold 517 Vertex Pharmaceuticals shares in Q2 2025, an estimated $251K.
  • Capital Wealth Planning first reported a position in Vertex Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Capital Wealth Planning's Vertex Pharmaceuticals position peaked at $251K in Q1 2025.
  • 1,562 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Capital Wealth Planning's 13F filing for Q2 2025, filed 7 Aug 2025.